DoPHIN 2

DoPlHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission of HIV through research into a new HIV drug called dolutegravir.

The study will assess the safe and effective use of this drug for improving child health outcomes in a cohort in Uganda, led by the Infectious Diseases Institute and in South Africa, led by the University of Cape Town. The Liverpool International Child Neurodevelopment and Disabilities Group will support neurodevelopmental follow-up in Uganda.